Improved Access to Orphan Drugs in the EU
Rare disease patients do not have equitable and timely access to the approved orphan drugs they need. This is often because the national authorities in their countries take too long to decide on the pricing and reimbursement of these drugs, thus delaying their market provision. EURORDIS is proposing a concrete measure to promote cooperation at European level in order to facilitate national decisions on pricing and reimbursement, thus reducing these delays and improving patients’ effective access to orphan drugs.
Read Eurordis Newsletter article (Dec 09) >